Skip to main content

NEW YORK – Sept. 8, 2016 – The LMG Life Sciences 2016 Guide’s “Life Science Stars” includes 13 shareholders from global law firm Greenberg Traurig, LLP. The guide serves as a resource for in-house counsel identifying leading lawyers and firms in multiple practice areas.

The following Greenberg Traurig shareholders were selected:

Scott J. Bornstein is co-chair of the firm's Global Intellectual Property & Technology Practice; chair of the firm's New York Intellectual Property & Technology Practice; co-chair of the firm's Global Patent Litigation Group; serves on the firm’s Executive Committee; and is a shareholder in the firm’s New York office. Bornstein has wide-ranging patent trial experience and has served as lead counsel in more than 100 patent litigations for a wide variety of national and international clients.

Robert P. Charrow, a shareholder in the firm’s Washington, D.C. office, focuses his practice on research, biotechnology, and health care issues. He represents health care providers, scientists, pharmaceutical companies, universities, research institutes, and other entities with respect to legislative, regulatory, and litigation matters arising under various federal laws and regulations.

Lori G. Cohen is chair of the firm’s Pharmaceutical, Medical Device & Health Care Litigation Practice; chair of the Trial Practice; co-chair of the Atlanta Litigation Practice; and is a shareholder in the firm’s Atlanta office. Her national litigation practice focuses on product liability litigation and, specifically, medical device and pharmaceutical litigation. Cohen has obtained 57 defense verdicts at trial.

David J. Dykeman, co-chair of the firm’s Global Life Sciences & Medical Technology Group, co-chair of firm’s Boston IP Group, and a shareholder in the firm’s Boston office, is a registered patent attorney with nearly 20 years of experience in patent and intellectual property law. Dykeman’s practice focuses on securing worldwide intellectual property protection and related business strategy for high-tech clients, with particular experience in life sciences, medical devices, biotechnology, health care, and information technology.

Robert L. Grossman, co-chair of the firm’s Israel Practice and a shareholder in the firm’s Miami office, focuses on securities, M&A, and corporate law with a wide-range of experience in taking companies public as well as acquiring and selling companies. Grossman has represented public and private companies, including companies in the medical device, pharmaceutical, biotechnology, health care, energy and natural resources, technology and software, and communications industries.

Eric D. Hargan, a shareholder in the firm’s Chicago office, focuses his practice on transactions, health care regulations, and government relations. Within the transactional area, he focuses on private equity, corporate finance, and mergers and acquisitions transactions in the health care sector. He previously served as a senior official at the U.S. Department of Health and Human Services.

Melissa Hunter-Ensor, Ph.D., a shareholder and registered patent attorney in the firm’s Boston office, focuses her practice on the intellectual property and commercial needs of clients in the life science industry. She has experience representing clients throughout the business cycle with patent portfolio management and strategic alliances, litigation and pre-litigation strategy, as well as in assessing the IP risks of target investments and conducting IP patent and licensing due diligence.

David C. Peck, co-chair of the Life Sciences & Medical Technology Group and a shareholder in the firm’s Fort Lauderdale office, works with emerging growth companies, established entities, and private equity firms in executing their strategic plans. He assists companies beginning with corporate formation, obtaining and structuring both equity and debt financing, mergers and acquisitions, as well as the integration of acquired operations, undertaking initial public offerings, and continuing through to liquidity and exit strategies.

Richard C. Pettus, shareholder in the firm’s New York office, has 20 years of experience in the litigation and trial of patent matters in the pharmaceutical and medical device fields, with a particular focus on Paragraph IV Hatch-Waxman litigation. He has represented clients in over 60 patent litigations, including more than 10 trials to verdict, and dozens of other matters that were successfully resolved via pre-trial dismissals, summary judgments and pro-competitive settlements.

Ginger Pigott, vice-chair of the firm’s Pharmaceutical, Medical Device & Health Care Litigation Practice and a shareholder in the firm’s Los Angeles office, focuses her practice on products liability litigation and commercial litigation. A particular focus of her practice lies in the defense of complex medical device and pharmaceutical products liability litigation, as well as counseling on pre-litigation issues including risk assessment, exposure reduction and mitigation and claims handling.

Justin J. Prochnow, a shareholder in the firm’s Denver office, focuses his practice on assisting companies with regulatory, business, and legal needs in the beverage, food, dietary supplement, cosmetic, medical device, and OTC industries. Prochnow works closely with companies to ensure regulatory compliance with statutes and regulations enforced by the Food and Drug Administration, the Federal Trade Commission, and other regulatory agencies.

Barry J. Schindler, co-chair of the firm’s Global Patent Prosecution Group and shareholder in the firm’s New Jersey office, has more than 25 years of experience in all aspects of pharmaceutical and chemical patent prosecution, representing major pharmaceutical and chemical companies regarding patents relating to small molecules and synthetic compounds. He also has wide-ranging patent experience in such areas as medical devices, business method processes, food products/supplements, telemedicine, internet-based systems, and plastics.

Nancy E. Taylor, co-chair of the Health & FDA Business Practice and shareholder in the firm’s Washington, D.C. office, has broad experience in areas relating to the Affordable Care Act provisions, CMS reimbursement, and policy issues relating to providers and plans, and she has done a significant amount of FDA regulatory work. Before joining Greenberg Traurig, Taylor served 10 years as Health Policy Director for the Senate Committee on Labor and Human Resources.

According to its website, LMG Life Sciences’ research involved over 1,000 online surveys and interviews with nearly 600 attorneys in the United States, as well as a review of public information and feedback from clients within the industry. This qualitative process of peer opinion, market feedback, and independent research led to their list of highest profile, most sought-after, and best-attorneys working in life sciences.

About Greenberg Traurig’s Life Sciences & Medical Technology Group

Greenberg Traurig’s Life Sciences & Medical Technology Group advises clients ranging from startups to large multinational public companies to leading research institutions. The group’s attorneys work closely with clients, providing innovative legal counsel to help them achieve their objectives – from discovery through commercialization and product marketing.

About Greenberg Traurig, LLP

Greenberg Traurig, LLP (GTLaw) has more than 2,000 attorneys in 38 offices in the United States, Latin America, Europe, Asia and the Middle East and is celebrating its 50th anniversary. One firm worldwide, GTLaw has been recognized for its philanthropic giving, was named the largest firm in the U.S. by Law360 in 2017, and among the Top 20 on the 2016 Am Law Global 100. Web: Twitter: @GT_Law.